Anti-CD4 therapy in rheumatoid arthritis
Van der Lubbe, P.A.; Reiter, C.; Riethmüller, G.; Breedveld, F.C.
Clinical and Experimental Rheumatology 11(Suppl 8): S151
1993
ISSN/ISBN: 0392-856X PMID: 8324941 Document Number: 408074
Document emailed within 1 workday
Related Documents
Furst, D.E.; Schiff, M.H.; Fleischmann, R.M.; Strand, V.; Birbara, C.A.; Compagnone, D.; Fischkoff, S.A.; Chartash, E.K. 2003: Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis) Journal of Rheumatology 30(12): 2563-2571Burmester, G.R.; Emmrich, F. 1993: Anti-CD4 therapy in rheumatoid arthritis Clinical and Experimental Rheumatology 11(Suppl 8): S139-S145
Choy, E.H.; Kingsley, G.H. 1993: Anti-CD4 therapy in rheumatoid arthritis Clinical and Experimental Rheumatology 11(Suppl 8): S147-S149
Maini, R.N.; Brennan, F.M.; Williams, R.; Chu, C.Q.; Cope, A.P.; Gibbons, D.; Elliott, M.; Feldmann, M. 1993: TNF-alpha in rheumatoid arthritis and prospects of anti-TNF therapy Clinical and Experimental Rheumatology 11(Suppl 8): S173-S175
Mignone, F.; Sardella, M.L.; Clara, L.; Barbero, I.; Bevivino, T.; Ciravegna, P. 1987: Selective anti-inflammatory therapy in infantile rheumatoid arthritis Minerva Pediatrica 39(9): 403-408
Feldmann, M.; Brennan, F.; Paleolog, E.; Taylor, P.; Maini, R.N. 1997: Anti-tumor necrosis factor alpha therapy of rheumatoid arthritis. Mechanism of action European Cytokine Network 8(3): 297-300
Straub, R.H.; Härle, P.; Atzeni, F.; Weidler, C.; Cutolo, M.; Sarzi-Puttini, P. 2005: Sex hormone concentrations in patients with rheumatoid arthritis are not normalized during 12 weeks of anti-tumor necrosis factor therapy Journal of Rheumatology 32(7): 1253-1258
Antoni, C.; Kalden, J.R. 1999: Combination therapy of the chimeric monoclonal anti-tumor necrosis factor alpha antibody (infliximab) with methotrexate in patients with rheumatoid arthritis Clinical and Experimental Rheumatology 17(6 Suppl 18: S73-S77
Kuru, O.; Bilgici, A.; Birinci, A.; Ulusoy, H.; Durupinar, B. 2009: Prognostic value of anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis Bratislavske Lekarske Listy 110(10): 650-654
Dombrecht, E.J.; Aerts, N.E.; Schuerwegh, A.J.; Hagendorens, M.M.; Ebo, D.G.; Van Offel, J.F.; Bridts, C.H.; Stevens, W.J.; De Clerck, L.S. 2006: Influence of anti-tumor necrosis factor therapy (Adalimumab) on regulatory T cells and dendritic cells in rheumatoid arthritis Clinical and Experimental Rheumatology 24(1): 31-37
Sun, J.; Zhang, Y.; Liu, L.; Liu, G. 2014: Diagnostic accuracy of combined tests of anti cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis: a meta-analysis Clinical and Experimental Rheumatology 32(1): 11-21
Yamane, T.; Hashiramoto, A.; Tanaka, Y.; Tsumiyama, K.; Miura, Y.; Shiozawa, K.; Chihara, K.; Shiozawa, S. 2008: Easy and accurate diagnosis of rheumatoid arthritis using anti-cyclic citrullinated peptide 2 antibody, swollen joint count, and C-reactive protein/rheumatoid factor Journal of Rheumatology 35(3): 414-420
Goodwin, J.S.; Ceuppens, J.L.; Rodriguez, M.A. 1983: Administration of nonsteroidal anti-inflammatory agents in patients with rheumatoid arthritis. Effects on indexes of cellular immune status and serum rheumatoid factor levels JAMA 250(18): 2485-2488
Sihvonen, S.; Korpela, M.; Mustila, A.; Mustonen, J. 2005: The predictive value of rheumatoid factor isotypes, anti-cyclic citrullinated peptide antibodies, and antineutrophil cytoplasmic antibodies for mortality in patients with rheumatoid arthritis Journal of Rheumatology 32(11): 2089-2094
Kim, D.-A.; Jearn, L.-H.; Kim, T.-Y. 2007: Antiperinuclear factor test is more useful than anti-Sa assay when used with anti-cyclic citrullinated peptide test in diagnosis of rheumatoid arthritis Journal of Rheumatology 34(9): 1944-1945
Breedveld, F.C.; de Vries, R.R. 1992: Anti-CD4 antibodies in rheumatoid arthritis Clinical and Experimental Rheumatology 10(4): 325-326
Juhl, P.; Thudium, C.S.; Gudmann, N.S.; Karsdal, M.A.; Bay-Jensen, A.-C.; Siebuhr, A.S. 2018: IL-6 receptor inhibition modulates type IIi collagen and C-reactive protein degradation in rheumatoid arthritis patients with an inadequate response to anti-tumour necrosis factor therapy: analysis of connective tissue turnover in the tocilizumab RADIATE study Clinical and Experimental Rheumatology 36(4): 568-574
Youinou, P.; Brousse, A.; Le Goff, P. 1984: Anti-histone antibodies in rheumatoid arthritis Revue du Rhumatisme et des Maladies Osteo-Articulaires 51(7-8): 419-420
Pybus, P.K. 1983: Anti-amoebic drugs in rheumatoid arthritis South African Medical Journal 63(2): 31
Afzal, N.; Karim, S.; Tafazzul-e-Mahmud, H.; Sami, W.; Arif, M.; Abbas, S. 2011: Evaluation of Anti-CCP Antibody for Diagnosis of Rheumatoid Arthritis Clinical Laboratory 57(11-12): 895-899